Inicio › Síndromes mielodisplásicos › Ohio
Ensayos clínicos de Síndromes mielodisplásicos en Ohio
22 estudios sobre Síndromes mielodisplásicos buscan participantes en Ohio.
Ciudades en Ohio
Texto oficial del estudio (inglés)
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Gabrail Cancer Center Research, Canton
- Cleveland Clinic - Cleveland, Cleveland
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT06499285HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
ReclutandoEstudio observacional
Edades de 12 a 80 · Todos los sexos · Actualizado el 6 nov 2026 · NCT07145411Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT05308264A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
- Cleveland clinic OH, Cleveland
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT07422480Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06577441MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT05564390Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
ReclutandoEstudio observacional
2 Months · Todos los sexos · Actualizado el 27 oct 2026 · NCT00900198Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Cleveland Clinic, Cleveland
- The Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT05320198Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- Cleveland Clinic Cancer Center, Cleveland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2026 · NCT06543381Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Ohio State University, The James Comprehensive Cancer, Columbus
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 oct 2026 · NCT06846606A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT04256317Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT06904482Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT03471260Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- y 3 más
ReclutandoFase 1/2
Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- GSK Investigational Site, Canton
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jun 2026 · NCT068478675-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
- Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
ReclutandoFase 1 temprana
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 may 2026 · NCT04187703Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- Ohio State University Medical Center, Columbus
ReclutandoFase 1
Edades de 18 a 65 · Todos los sexos · Actualizado el 25 mar 2026 · NCT03533816A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- The Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 24 mar 2026 · NCT04988555HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
ReclutandoFase 2
3 Months · Todos los sexos · Actualizado el 12 nov 2025 · NCT02143830SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2025 · NCT06501196De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.